Browse > Article

Dlx3 Plays a Role as a Positive Regulator of Osteoclast Differentiation  

Cha, Ji-Hun (Department of Cell & Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University)
Ryoo, Hyun-Mo (Department of Cell & Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University)
Woo, Kyung-Mi (Department of Cell & Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University)
Kim, Gwan-Shik (Department of Cell & Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University)
Baek, Jeong-Hwa (Department of Cell & Developmental Biology, School of Dentistry and Dental Research Institute, Seoul National University)
Publication Information
International Journal of Oral Biology / v.32, no.3, 2007 , pp. 85-91 More about this Journal
Abstract
Dlx3 is a homeodomain protein and is known to playa role in development and differentiation of many tissues. Deletion of four base pairs in DLX3 (NT3198) is causally related to tricho-dento-osseous (TDO) syndrome (OMIM # 190320), a genetic disorder manifested by taurodontism, hair abnormalities, and increased bone density in the cranium. Although the observed defects of TDO syndrome involves bone, little is known about the role of Dlx3 in bone remodeling process. In this study, we examined the effect of wild type DLX3 (wtDlx3) expression on osteoclast differentiation and compared it with that of 4-BP DEL DLX3 (TDO mtDlx3). To examine whether Dlx3 is expressed during RANKL-induced osteoclast differentiation, RAW264.7 cells were cultured in the presence of receptor activator of nuclear factor-B ligand (RANKL). Dlx3 protein level increased slightly after RANKL treatment for 1 day and peaked when the fusion of prefusion osteoclasts actively progressed. When wtDlx3 and TDO mtDlx3 were overexpressed in RAW264.7 cells, they enhanced RANKL-induced osteoclastogenesis and the expression of osteoclast differentiation marker genes such as calcitonin receptor, vitronectin receptor and cathepsin K. Since osteoclast differentiation is critically regulated by the balance between RANKL and osteoprotegerin (OPG), we examined the effect of Dlx3 overexpression on expression of RANKL and OPG in C2C12 cells in the presence of bone morphogenetic protein 2. Overexpression of wtDlx3 enhanced RANKL mRNA expression while slightly suppressed OPG expression. However, TDO mtDlx3 did not exert significant effects. This result suggests that inability of TDO mtDlx3 to regulate expression of RANKL and OPG may contribute to increased bone density in TDO syndrome patients. Taken together, it is suggested that Dlx3 playa role as a positive regulator of osteoclast differentiation via up-regulation of osteoclast differentiation-associated genes in osteoclasts, as well as via increasing the ratio of RANKL to OPG in osteoblastic cells.
Keywords
Dlx3; TDO mutant Dlx3; Osteoclast differentiation; RANKL; OPG;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Anderson, S.A., Eisenstat, D.D., Shi, L. and Rubenstein, J.L.: Interneuron migration from basal forebrain to neocortex: dependence on Dlx genes. Science 278:474-476, 1997   DOI   ScienceOn
2 Koide, M., Murase, Y., Yamato, K., Noguchi, T., Okahashi, N. and Nishihara, T.: Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1 alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem. Biophys. Res. Commun. 259:97-102, 1999   DOI   ScienceOn
3 Luchin, A., Suchting, S., Merson, T., Rosol, T.J., Hume, D.A., Cassady, A.I. and Ostrowski, M.C.: Genetic and physical interactions between Microphthalmia transcription factor and PU.1 are necessary for osteoclast gene expression and differentiation. J. BioI. Chem. 276:36703-36710, 2001   DOI   ScienceOn
4 Price, J.A., Bowden, D.W., Wright, J.T., Pettenati, M.J. and Hart, T.C.: Identification of a mutation in DLX3 associated with tricho-dento-osseous (TDO) syndrome. Hum. Mol. Genet. 7:563-569, 1998a   DOI   ScienceOn
5 Sharma, S.M., Bronisz, A., Hu, R., Patel, K., Mansky, K.C., Sif, S. and Ostrowski, M.C.: MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J. BioI. Chem. 282:15921-15929, 2007   DOI   ScienceOn
6 Simonet, W.S., Lacey, D.L., Dunstanm, C.R., Kelleym, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Wooden, S., Bennett, L., Boone, T., Shimomoto, G. and De Rose, M.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:303-319, 1997
7 Ishii, M., Iwai, K., Koike, M., Ohshima, S., Kudo-Tanaka, E., Ishii, T., Mima, T., Katada, Y, Miyatake, K., Uchiyama, Y. and Saeki, Y.: RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. J. Bone Miner. Res. 21:965-976, 2006   DOI   ScienceOn
8 Marks, S.C. Jr. and Walker, D.G.: The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors. Am. J. Anat. 161:1-10, 1981   DOI   ScienceOn
9 Nagai, M. and Sato, N.: Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem. Biophys. Res. Commun. 257:719-723, 1999   DOI   ScienceOn
10 Collin-Osdoby, P., Yu, X., Zheng, H. and Osdoby, P.: RANKL-mediated osteoclast formation from murine RAW264.7 cells. Methods Mol. Med. 80:153-166, 2003
11 Hassan, M.Q., Tare, R.S., Lee, S.H., Mandeville, M., Morasso, M.I., Javed, A., van Wijnen, A.J., Stein, J.L., Stein, G.S. and Lian, J.B.: BMP2 commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network. J. BioI. Chem. 281:40515-40526, 2006   DOI   ScienceOn
12 Otsuka, E., Notoya, M. and Hagiwara, H.: Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. Calcif. Tissue Int. 73:72-77, 2003   DOI
13 Price, J.A., Wright, J.T., Kula, K., Bowden, D.W. and Hart, T.C.: A common DLX3 gene mutation is responsible for tricho-dento-osseous syndrome in Virginia and North Carolina families. J. Med. Genet. 35:825-828, 1998b   DOI
14 Quinn, J.M.W., Elliott, J., Gillespie, M.T. and Martin, T.J.: A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139:4424-4427, 1998   DOI   ScienceOn
15 Hassan, M.Q., Javed, A., Morasso, M.I., Karlin, J., Montecino, M., Wijnen, A.J.V., Stein, G.S., Stein, J.L. and Lian J.B.: Dlx3 transcriptional regulation of osteoblast differentiation: temporal recruitment of Msx2, Dlx3 and Dlx5 homeodomain proteins to chromatin of the osteocalcin gene. Mol. Cell. BioI. 24:9248-9261, 2004   DOI   ScienceOn
16 Matsuo, K., Galson, D.L., Zhao, C., Peng, L., Laplace, C., Wang, K.Z., Bachler, M.A., Amano, H., Aburatani, H., Ishikawa, H. and Wagner, E.F.: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. BioI. Chem. 279:26475-26480, 2004   DOI   ScienceOn
17 Ghanem, N., Jarinova, O., Amores, A., Long, Q., Hatch, G., Park, B.K., Rubenstein, J.L.R. and Ekker, M.: Regulatory roles of conserved intergenic domains in vertebrate Dlx bigene clusters. Genome Res. 13:533-543, 2003   DOI   ScienceOn
18 Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., Colombero, A., Elliot, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y.X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W.J.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998   DOI   ScienceOn
19 Ghoul-Mazgar, S., Hotton, D., Lezot, F., Blin- Wakkach, C., Asselin, A., Sautier, J.M. and Berdal, A.: Expression pattern of Dlx3 during cell differentiation in mineralized tissues. Bone 37:799-809, 2005   DOI   ScienceOn
20 Wright, J.T., Kula, K., Hall, K., Simmons, J.H. and Hart, T.C.: Analysis of the tricho-dento-osseous syndrome genotype and phenotype. Am. J. Med. Genet. 72:197-204, 1997   DOI   ScienceOn
21 Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T. and Martin, T.J.: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999   DOI   ScienceOn
22 Morasso, M.I., Markova, N.G. and Sargent, T.D.: Regulation of epidermal differentiation by a Distal-less homeodomain gene. J. Cell BioI. 135:1879-1887, 1996   DOI
23 Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S., Yano, K., Fujise, N., Sato, Y, Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T. and Higashio, K.: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337, 1998b   DOI   ScienceOn
24 Northrop, J.P., Ho, S.N., Chen, L., Thomas, D.J., Timmerman, L.A., Nolan, G.P., Admon, A. and Crabtree, G.R.: NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 369:497-502, 1994   DOI   ScienceOn
25 Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 95:3597-3602, 1998a
26 Aubin, J.E. and Bonnelye, E.: Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos. Int. 11:905-913, 2000   DOI
27 McGinnis, W. and Krumlauf, R.: Homeobox genes and axial patterning. Cell 68:283-302, 1992   DOI   ScienceOn